ANIP Ani Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIP

Price (delayed)

$65.36

Market cap

$1.38B

P/E Ratio

76

Dividend/share

N/A

EPS

$0.86

Enterprise value

$1.44B

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), ...

Highlights
Ani Pharmaceuticals's net income has surged by 139% YoY and by 40% QoQ
The company's EPS has surged by 128% YoY and by 62% QoQ
ANIP's quick ratio is up by 20% year-on-year but it is down by 5% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.anipharmaceuticals.com/
Peers: JAZZ TEVA PFE CAH

Key stats

What are the main financial stats of ANIP
Market
Shares outstanding
21.08M
Market cap
$1.38B
Enterprise value
$1.44B
Valuations
Price to earnings (P/E)
76
Price to book (P/B)
3.09
Price to sales (P/S)
2.44
EV/EBIT
30.81
EV/EBITDA
13.37
EV/Sales
2.96
Earnings
Revenue
$486.82M
EBIT
$46.81M
EBITDA
$107.87M
Free cash flow
$110.09M
Per share
EPS
$0.86
Free cash flow per share
$6.05
Book value per share
$21.17
Revenue per share
$26.76
TBVPS
$36.67
Balance sheet
Total assets
$904.42M
Total liabilities
$446.82M
Debt
$285.67M
Equity
$432.75M
Working capital
$374.34M
Liquidity
Debt to equity
0.66
Current ratio
3.57
Quick ratio
2.63
Net debt/EBITDA
0.6
Margins
EBITDA margin
22.2%
Gross margin
62.7%
Net margin
3.9%
Operating margin
9.9%
Efficiency
Return on assets
2%
Return on equity
4.3%
Return on invested capital
7.9%
Return on capital employed
6.2%
Return on sales
9.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIP stock price

How has the Ani Pharmaceuticals stock price performed over time
Intraday
0.63%
1 week
-0.18%
1 month
-6.02%
1 year
73.78%
YTD
18.53%
QTD
-5.45%

Financial performance

How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$486.82M
Gross profit
$305.3M
Operating income
$48.24M
Net income
$18.78M
Gross margin
62.7%
Net margin
3.9%
Ani Pharmaceuticals's net income has surged by 139% YoY and by 40% QoQ
The net margin has soared by 126% YoY and by 30% QoQ
The gross profit has surged by 72% year-on-year and by 7% since the previous quarter
Ani Pharmaceuticals's revenue has soared by 54% YoY and by 8% from the previous quarter

Growth

What is Ani Pharmaceuticals's growth rate over time

Valuation

What is Ani Pharmaceuticals stock price valuation
ANIP P/E details
P/E
76
P/B
3.09
P/S
2.44
EV/EBIT
30.81
EV/EBITDA
13.37
EV/Sales
2.96
The company's EPS has surged by 128% YoY and by 62% QoQ
The company's equity rose by 38% YoY
The P/B is 28% above the 5-year quarterly average of 2.4 and 23% above the last 4 quarters average of 2.5
Ani Pharmaceuticals's revenue has soared by 54% YoY and by 8% from the previous quarter
The price to sales (P/S) is 10% higher than the last 4 quarters average of 2.2

Efficiency

How efficient is Ani Pharmaceuticals business performance
The company's return on sales has surged by 188% YoY and by 3.2% QoQ
The ROA has soared by 130% YoY and by 43% from the previous quarter
The return on equity has surged by 127% year-on-year and by 34% since the previous quarter
Ani Pharmaceuticals's ROIC has increased by 13% from the previous quarter

Dividends

What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIP.

Financial health

How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 102% more than its total liabilities
ANIP's quick ratio is up by 20% year-on-year but it is down by 5% since the previous quarter
Ani Pharmaceuticals's total assets has increased by 19% YoY
The debt is 34% lower than the equity
The company's equity rose by 38% YoY
The debt to equity has decreased by 27% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.